Welcome to our dedicated page for Biodexa Pharmaceuticals plc news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals plc stock.
Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company whose news flow centers on the clinical and regulatory progress of its lead programs eRapa, tolimidone and MTX110. Company announcements and SEC Form 6-K filings describe ongoing activity in familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes and rare or orphan brain cancers.
Investors following BDRX news can expect regular updates on the Serenta Phase 3 trial of eRapa in FAP, including milestones such as enrollment of the first patients, activation of new clinical sites in the United States and Europe, and approval of a Clinical Trial Application by the European Medicines Agency. Releases also provide context on the FAP disease burden and the lack of approved non-surgical treatment options, which frame the rationale for eRapa’s development.
Biodexa’s news stream also covers pipeline developments beyond FAP. The company reports progress in a Phase 2 study of eRapa in NMIBC, a Phase 2a investigator-initiated trial of tolimidone in type 1 diabetes, and early-stage studies of MTX110 in aggressive brain cancers. Operational updates, such as orphan drug designations, Fast Track designation, and collaborations with organizations like Emtora Biosciences, LumaBridge and Precision for Medicine, feature prominently.
In addition, BDRX news includes corporate and financing events such as equity line agreements, warrant transactions, ADR ratio changes and public offerings of ADS Units and pre-funded units, as detailed in Form 6-K filings. Governance and leadership changes, including board appointments and executive role updates, are also disclosed through press releases. For readers tracking BDRX, this news page offers a consolidated view of clinical milestones, regulatory steps and capital markets activity related to Biodexa’s development programs.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has announced a General Meeting scheduled for June 11, 2025, at their Cardiff offices. The company is proposing four key resolutions: (1) subdivision of each issued ordinary share of £0.001 into one ordinary share of £0.00005 and 19 C deferred shares of £0.00005, (2) authorization for Directors to allot shares up to £476,954.10 nominal value until 2028 AGM, (3) empowerment of Directors to allot equity securities for cash without pre-emption rights, and (4) adoption of new articles of association.
The primary purpose of these resolutions is to lower the par value of ordinary shares and enable the company to issue shares above par value. Importantly, the company states that these changes will not affect the number of outstanding ordinary shares or American Depositary Shares.
Biodexa Pharmaceuticals (Nasdaq: BDRX) held a General Meeting on May 2, 2025, where two ordinary resolutions received majority votes of 62% and 61%. However, a crucial special resolution (Resolution 3) failed to pass, receiving 71% of votes when it needed 75%. Since Resolution 1 was dependent on Resolution 3's approval, it also failed despite its majority vote. The failed Resolution 3 was aimed at reducing the nominal value of shares to provide more flexibility in future fundraising efforts. The company's Chairman, Dr. Stephen Parker, indicated that alternative proposals will be presented in the future.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has announced a General Meeting scheduled for May 2, 2025, at 13:00 BST at their Cardiff offices. The meeting will address three key resolutions:
1. Subdivision of each issued ordinary share (£0.00005) into one ordinary share (£0.000001) and 49 D deferred shares (£0.000001)
2. Approval of directors' remuneration policy
3. Adoption of new articles of association
The primary objective of these resolutions is to reduce the par value of ordinary shares, enabling the company to issue shares above par value. The company emphasizes that these changes will not affect the number of outstanding ordinary shares or American Depositary Shares.
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has released its audited preliminary financial results for the fiscal year ending December 31, 2024. The company, which positions itself as an acquisition-focused clinical stage biopharmaceutical company, is developing a pipeline of innovative products targeting diseases with unmet medical needs.
Biodexa Pharmaceuticals (NASDAQ:BDRX) is advancing towards initiating a Phase 3 trial for eRapa, its proprietary encapsulated rapamycin formulation for treating familial adenomatous polyposis (FAP). The company recently achieved key milestones including FDA Fast Track designation and a successful Type C meeting.
The Phase 3 study will be a double-blind placebo-controlled trial involving approximately 168 high-risk FAP patients across 30 clinical sites in the U.S. and Europe. The trial is substantially funded with a $17 million grant from the Cancer Prevention Research Institute of Texas, matched by $8.5 million from Biodexa.
The company's Phase 2 trial demonstrated promising results, with cohort 2 showing an 89% non-progression rate and 29% median reduction in polyp burden at 12 months. Biodexa has appointed LumaBridge and Precision for Medicine as CROs for the U.S. and European components respectively.